This 2014 systematic review synthesizes prevalence data for all muscular dystrophy types from 38 studies across 19 countries (1960–2013). It asks: how common are these disorders in the general population, and how reliable are existing estimates? The answer matters for resource allocation, research funding, and understanding the true burden of these conditions.
Before this review, no synthesis existed of prevalence across all muscular dystrophy subtypes in the general population. Estimates varied enormously, making it difficult to compare disease burden or justify resource allocation.
For the orthopedic trainee, these numbers matter most when a child presents with proximal muscle weakness, Gowers sign, or delayed walking. Duchenne affects roughly 1.7–4.2 per 100,000 of the general population, but its true burden is underestimated because affected patients die before age 20, reducing point prevalence. When you see a young boy with a waddling gait or calf pseudohypertrophy, the diagnostic workup starts with serum CPK, EMG, muscle biopsy, and genetic testing.
Myotonic dystrophy, the most prevalent type, affects multiple organ systems beyond muscle (including cardiac conduction and the endocrine system). Patients may present to orthopedics with contractures, footdrop, or spine deformity before a systemic diagnosis is established.
This paper is foundational for understanding why rare disease registries and standardized reporting matter: without consistent methodology, prevalence estimates are unreliable, and health systems cannot plan appropriately for these patients.
This 2014 systematic review synthesizes prevalence data for all muscular dystrophy types from 38 studies across 19 countries (1960–2013). It asks: how common are these disorders in the general population, and how reliable are existing estimates? The answer matters for resource allocation, research funding, and understanding the true burden of these conditions.
Before this review, no synthesis existed of prevalence across all muscular dystrophy subtypes in the general population. Estimates varied enormously, making it difficult to compare disease burden or justify resource allocation.
For the orthopedic trainee, these numbers matter most when a child presents with proximal muscle weakness, Gowers sign, or delayed walking. Duchenne affects roughly 1.7–4.2 per 100,000 of the general population, but its true burden is underestimated because affected patients die before age 20, reducing point prevalence. When you see a young boy with a waddling gait or calf pseudohypertrophy, the diagnostic workup starts with serum CPK, EMG, muscle biopsy, and genetic testing.
Myotonic dystrophy, the most prevalent type, affects multiple organ systems beyond muscle (including cardiac conduction and the endocrine system). Patients may present to orthopedics with contractures, footdrop, or spine deformity before a systemic diagnosis is established.
This paper is foundational for understanding why rare disease registries and standardized reporting matter: without consistent methodology, prevalence estimates are unreliable, and health systems cannot plan appropriately for these patients.